Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2017

View Archived Issues

Sanofi reflects on accomplishments of first quarter 2017

Shire reviews progress of first quarter 2017

Vaccine against respiratory syncytial virus ChAd155-RSV safe in first-in-human study

Repurposing trazodone hydrochloride and dibenzoylmethane for the treatment of dementia

Teprotumumab demonstrates clinical benefit in patients with thyroid-associated ophthalmopathy

EC approves Merck & Co.'s Keytruda in classical Hodgkin's lymphoma

FDA approves Radicava for ALS

Achaogen, Bill & Melinda Gates Foundation partner to prevent neonatal sepsis in developing countries

Bristol-Myers Squibb initiates phase II trial of BMS-986168 in progressive supranuclear palsy

Phase I data presented for acid pump antagonist DWP-14012

Aridis conducts phase II trial of Aerucin for P. aeruginosa pneumonia

CONCERTO trial of laquinimod in RRMS fails to meet primary endpoint

Proterris and Alfama merger completed

New animal model reproduces hepatitis D virus infection

Faron's phase III trial of Traumakine in ARDS cleared to continue by IMDC

Bristol-Myers Squibb divulges novel NR2B receptor ligands

Immunocore identifies new ImmTAC lead molecule under collaboration with GSK

Princeton Drug Discovery patents protein kinase inhibitors

Bayer describes new antiangiogenic compounds

Esteve discloses new sigma1-receptor ligands

Mitsubishi Tanabe Pharma presents novel KAT II inhibitors

Neuform Pharmaceuticals identifies new IDH2 inhibitors

Preclinical data presented for [18F]ODS-2004436, a TKI-PET radiotracer targeting EGFR

Novel BRD4 inhibitors patented by the NEOMED Institute

BioLineRx's meeting with FDA paves way for pivotal study of BL-8040 for stem cell mobilization

Horizon Pharma to acquire River Vision Development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...